NCT05348941

Efficacy and Safety of D-chiro-inositol in Obese Patients

Evaluation o Efficacy and Safety of D-chiro-inositol in Insulin Resistant, Obese Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Lo.Li.Pharma s.r.l · Industry
• Sex: Female
• Age: 25 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The study aims to evaluate the efficacy and tolerability of a food supplement based on D-chiro-inositol in overweight or obese women with insulin resistance, who are approaching a hypocaloric diet

Detailed description

Scientific studies on overweight/obese non-diabetic subjects have shown that weight loss improves insulin sensitivity. In fact, in these subjects weight loss reduces the insulin response to the oral glucose load and lowers plasma concentration of triglycerides. However, although the insulin value is reduced with diet, it does not reach the levels found in overweight/obese non-insulin resistant subjects. It has been shown that the supplementation of D-chiro-inositol (DCI), a polyol with an insulin-sensitizing action, can positively affect insulin resistance, avoiding the typical side effects of classic insulin sensitizers. In fact, DCI improves glucose tolerance and increases insulin sensitivity, as demonstrated in hyperinsulinemic women with polycystic ovary syndrome. Therefore, considering the role of DCI, we want to investigate the efficacy and tolerability of a DCI-based product in overweight / obese women with insulin resistance who are approaching a low-calorie diet.

Conditions

• Insulin Resistance

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	TECADRIOL	Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin

Timeline

• Start date: 2022-06-28
• Primary completion: 2022-09-27
• Completion: 2023-11-01
• First posted: 2022-04-27
• Last updated: 2025-06-04

Locations

1 site across 1 country: Italy